Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Corvus Pharmaceuticals Q3 2026 Results: Net Loss of $20.3M, Loss Widens

Corvus Pharmaceuticals reported a significant increase in net loss to $52.0 million for the nine months ended September 30, 2026, compared to $3.0 million in the prior year, primarily driven by a $21.1 million increase in research and development expenses. The company's cash position strengthened considerably to $203.0 million in cash and marketable securities following a follow-on public offering that raised $189.4 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-19.5-9.8
Net income-20.3-10.2
EPS (diluted, $ a share)$-0.22$-0.12

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: CRVS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Corvus Pharmaceuticals, Inc.: key numbers

Share price
$10.60Close, Nov 16
Market cap
$894M
Shares outstanding
84.35MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Corvus Pharmaceuticals, Inc.

All →
5:55 PM ET Form 4
Insider Buying

Corvus Pharmaceuticals Chief Business Officer Jeffrey Arcara Buys $34.4K of Stock

Jeffrey Arcara, Chief Business Officer, bought 3,000 shares of Corvus Pharmaceuticals, Inc. at $11.46 a share, worth $34.4K in total on Nov 11, 2026. Shares held after the trade: 3,000.

Value
$34.4K
Shares
3,000
Price
$11.46
Role
Chief Business Officer
Trade date
Nov 11, 2026
4:03 PM ET 8-K
Financial Results

Corvus Pharmaceuticals Financial Results

Corvus Pharmaceuticals reported third quarter 2026 financial results and provided a business update on its soquelitinib clinical programs. The company ended the quarter with $202.9 million in cash and marketable securities, which is expected to provide a financial runway into the second quarter of 2028.

“We continue to drive the science and advance the breadth of potential clinical indications for ITK inhibition with soquelitinib. Our Phase 3 PTCL and Phase 2 atopic dermatitis clinical trials are on track and there has been strong interest in our new hidradenitis suppurativa trial. We also are making good progress towards initiating a unique asthma trial that will include both T2 and non-T2 patients by Q1 2027. We believe soquelitinib has the potential to be effective in both types of asthma patients based on its mechanism of action affecting Th2, Th17 and T regulatory cells, which we will be closely analyzing in our hidradenitis suppurativa trial. Taken altogether, we are positioned for a series of potentially significant data milestones across our soquelitinib development pipeline in 2027.”

Richard A. Miller, M.D., co-founder, president and chief executive officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.